A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia

Factor Xa would be ideally suited to control unregulated bleeding were it not for its extremely short half-life and tendency to overactivate clotting mechanisms. Ivanciu et al. show that a longer lived but less active variant of the protease restores hemostasis in mouse models of hemophilia without thrombotic complications.